Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1295-1311

  Gasparini, Giampietro ^a   Longo, Raffaele ^a   Fanelli, Massimo ^a   Teicher, Beverly A ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENDOTHELIAL CELL GROWTH FACTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GENISTEIN; IMATINIB; MINOCYCLINE; MONOCLONAL ANTIBODY DC101; PACLITAXEL; PROTEIN KINASE INHIBITOR; SEMAXANIB; SUNITINIB; SURAMIN; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB; VATALANIB; VINBLASTINE; VINCA ALKALOID;

ANGIOGENESIS; CHILL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG INHIBITION; EPIGENETICS; EPISTAXIS; HEADACHE; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; TUMOR GROWTH; CLASSIFICATION; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METHODOLOGY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; RESEARCH DESIGN;

EID: 14544305077     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.022     Document Type: Review

References (166)

1. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410, 2003
2. Longo R, Sarmiento R, Fanelli M, et al: Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis 5:237-256, 2002
3. St Croix B, Rago C, Velculescu V, et al: Genes expressed in human tumor and endothelium. Science 289:1197-1202, 2000
4. Bagley R, Walter-Yohrling J, Cao X, et al: Endothelial precursor cells as a model of tumor endothelium: Characterization and comparison to mature endothelial cells. Cancer Res 63:5866-5873, 2003
5. Luttun A, Carmeliet G, Carmeliet P: Vascular progenitors: From biology to treatment. Trends Cardiovasc Med 12:88-96, 2002
6. Asahara T, Masuda H, Takahashi T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228, 1999
7. Lin Y, Weisdorf DJ, Solovey A, et al: Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105:71-77, 2000
8. Rafii S: Circulating endothelial precursors: Mystery, reality, and promise. J Clin Invest 105:17-19, 2000
9. Shirakawa K, Furuhata S, Watanabe I, et al: Induction of vasculogenesis in breast cancer models. Br J Cancer 87:1454-1461, 2002
10. Capillo M, Mancuso P, Gobbi A, et al: Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9:377-382, 2003
11. Jackson C: Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens 11:295-299, 2002
12. Pepper MS: Role of the matrix metalloproteinases and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21:1104-1117, 2001
13. Eliceiri BP, Cheresh DA: The role of alpha-v integrin during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest 103:1227-1230, 1999
14. Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918-921, 2002
15. Brooks PC, Clark R, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 193:264:569-571, 1994
16. Burrows FJ, Derbyshire J, Tazzari PL, et al: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1:1623-1634, 1995
17. Shalaby F, Ho J, Stanford WL, et al: A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89:981-990, 1997
18. Gasparini G: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58:17-38, 1999
19. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13:31-36, 1991
20. Rak J, Kerbel RS: Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls. Cancer Metastasis Rev 15:231-236, 1996
21. Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15:39-48, 1997
22. Yu JL, Rak JW, Coomber BL, et al: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-1528, 2002
23. Liu W, Ahmad SA, Reinmuth N, et al: Endothelial cell survival and apoptosis in tumor vasculature. Apoptosis 5:323-328, 2000
24. Benjamin LE, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
25. Nor JE, Polverini PJ: Role of endothelial cell survival and death signals in angiogenesis. Angiogenesis 3:101-116, 1999
26. Tran J, Rak J, Sheehan C, et al: Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781-788, 1999
27. Tran J, Master Z, Yu JL, et al: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99:4349-4354, 2002
28. Rybak SM, Sanovich E, Hollingshead MG, et al: 'Vasocrine' formation of tumor cell-lined vascular spaces: Implications for rational design of antiangiogenic therapies. Cancer Res 63:2812-2819, 2003
29. Yu JL, Rak JW, Carmeliet P, et al: Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 158:1325-1334, 2001
30. Carmeliet P, Dor Y, Herbert JM, et al: Role of HIF-1 alpha in hypoxic-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490, 1998
31. Blagosklonny MV: Hypoxia-inducible factor: Achilles' heel of angiogenic cancer therapy, Int J Oncol 19:257-262, 2001
32. Folkman J: Looking for a good endothelial address. Cancer Cell 1:113-115, 2002
33. Sudhakar A, Sugimoto H, Yang C, et al: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta-3 and alpha-5 beta-1 integrins. Proc Natl Acad Sci U S A 100:4766-4771, 2003
34. Morbidelli L, Donnini S, Chillemi F, et al: Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 9:5358-5369, 2003
35. Keezer SM, Ivie SE, Krutzsch HC, et al: Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res 63:6405-6412, 2003
36. Kerbel RS: Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J Clin Oncol 19:45s-51s, 2001 (suppl)
37. Maier J, Delia D, Thorpe PE, et al: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 8:238-244, 1997
38. Auerbach R, Kubai L, Knioghton D, et al: A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 41:391-394, 1974
39. Grant DS, Tashiro K, Segui-Real B, et al: Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58:933-943, 1989
40. Ziche M, Donnini S, Morbidelli L, et al: Linomide blocks angiogenesis by breast carcinoma VEGF transfectants. Br J Cancer 77:1123-1129, 1998
41. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
42. Fidler IJ: Angiogenesis and cancer metastasis. Cancer J 6:S134-S141, 2000 (suppl 2)
43. Sweeney CJ, Miller KD, Sissons SE, et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372, 2001
44. Mauceri HJ, Hanna NN, Beckett MA, et al: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291, 1998
45. Yokoyama Y, Dhanabal M, Griffioen AW, et al: Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res 60:2190-2196, 2000
46. Teicher BA: A systems approach to cancer therapy: Antiangiogenics + standard cytotoxics mechanism(s) of interaction. Cancer Metastasis Rev 15:247-272, 1996
47. Herbst RS, Takeuchi H, Teicher BA: Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemother Pharmacol 41:497-504, 1998
48. Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Investig Drugs 12:51-64, 2003
49. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999
50. Teicher BA, Dupuis NP, Robinson M, et al: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7:237-243, 1995
51. Teicher BA, Holden SA, Ara G, et al: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 57:920-925, 1994
52. Teicher BA, Alvarez E, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
53. Teicher BA, Dupuis N, Kusomoto T, et al: Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 2:269-276, 1995
54. Inoue K, Chikazawa M, Fukata S, et al: Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 9:886-899, 2003
55. Satoh H, Ishikawa H, Fujimoto M, et al: Combined effects of TNP-470 and taxol in human non-small cell lung cancer cell lines. Anticancer Res 18:1027-1030, 1998
56. Shishido T, Yasoshima T, Denno R, et al: Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 89:963-969, 1998
57. Ogawa H, Sato Y, Kondo M, et al: Combined treatment with TNP-470 and 5-fluorouracil effectively inhibits growth of murine colon cancer cells in vitro and liver metastasis in vivo. Oncol Rep 7:467-472, 2000
58. Inoue K, Slaton JW, Perrotte P, et al: Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874-4884, 2000
59. Inoue K, Slaton JW, Davis DW, et al: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC 101 and paclitaxel. Clin Cancer Res 6:2635-2643, 2000
60. Kim SJ, Uehara H, Karashima T, et al: Blockage of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9:1200-1210, 2003
61. Bergers G, Javaherian K, Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999
62. Gasparini G: Metronomic scheduling: The future of chemotherapy? Lancet Oncol 2:733-740, 2001
63. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
64. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:15-24, 2000
65. Hida T, Kozaki K, Muramatsu H, et al: Cyclo-oxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6:2006-2011, 2000
66. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
67. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003
68. Fong TA, Shawver LK, Sun L, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor (Flk-1/KDR) that inhibitors tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res 59:99-106, 1999
69. Geng L, Donnelly E, McMahon G, et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413-2419, 2001
70. Ning S, Laird D, Cherrington JM, et al: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157:45-51, 2002
71. Krystal GW, Honsawek S, Kiewlich D, et al: Indoline tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells. Cancer Res 61:3660-3668, 2001
72. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
73. Drevs J, Hofmann I, Hugenschmidt H, et al: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824, 2000
74. Hurwitz H, Holden SN, Eckhardt SG, et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc Am Soc Clin Oncol 21:82a, 2002 (abstr 325)
75. Goekjian PG, Jirousek MR: Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10:2117-2140, 2001
76. Swannie HC, Kaye SB: Protein kinase C inhibitors. Curr Oncol Rep 4:37-46, 2002
77. Teicher BA, Alvarez E, Menon K, et al: Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol 49:69-77, 2002
78. Keyes K, Mann L, Cox K, et al: Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol 51:321-327, 2003
79. Teicher BA, Menon K, Alvarez E, et al: Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 7:634-640, 2001
80. Herbst RS, Thornton DE, Kies MS, et al: Phase 1 study of LY317615, a protein kinase C beta inhibitor. Proc Am Soc Clin Oncol 21:82a, 2002 (abstr 326)
81. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 29:10-14, 2002
82. Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 19:851-856, 2001
83. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
84. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
85. Gasparini G, Longo R, Sarmiento R, et al: COX-2 inhibitors (Coxibs): A new class of anticancer agents? Lancet Oncol 4:605-615, 2003
86. Hurwitz H, Fehrenbacher L, Cartwright T, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
87. De Vore RF, Fehrenbacher Rs, Herbst RS: A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19:485a, 2000 (abstr 1896)
88. Sledge GW Jr: Breast cancer in the clinic: Treatments past, treatments future. J Mammary Gland Biol Neoplasia 6:487-495, 2001
89. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
90. Rosen LS: Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9:36-44, 2002 (suppl 2)
91. Kuenen BC, Rosen L, Smit EF, et al: Dose-finding and pharmacokinetics study of cisplatin, gemcitabine and SU5416 in patients with solid tumors. J Clin Oncol 20:1657-1667, 2002
92. Hoekman K, Kuenen B, Levi M, et al: Activation of the coagulation cascade and endothelial cell perturbation during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Proc Am Soc Clin Oncol 21:6a, 2002 (abstr 21)
93. Aklilu M, Kindler HL, Gajewski TF, et al: Toxicities of the antiangiogenic agent SU5416 in phase II studies. Proc Am Soc Clin Oncol 21:28b, 2002 (abstr 1921)
94. Harris AL: Von Hippel-Landau syndrome: Target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist 5:32-36, 2000 (suppl 1)
95. Raymond E, Faivre S, Vera K, et al: Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-targeted tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 22:192, 2003 (abstr 769)
96. Rosen L, Mulay M, Long J, et al: Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 765)
97. Demetri GD, George S, Heinrich MC, et al: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (gist) refractory to imatinib. Proc Am Soc Clin Oncol 22:814, 2003 (abstr 3273)
98. Manning WC, Bello CL, Deprimo SE, et al: Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients (pts) with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22:192, 2003 (abstr 768)
99. O'Farrell A-M, Deprimo SE, Manning WC, et al: Analysis of biomarkers of SU11248 action in an exploratory study in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:234, 2003 (abstr 939)
100. Toner GC, Mitchell PL, De Boer R, et al: PET imaging study of SU11248 in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 767)
101. Steward WP, Thomas AL, Morgan TB, et al: Extended phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:274, 2003 (abstr 1098)
102. Trarbach T, Schleucher N, Riedel U, et al: Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ ZK222584 (PTK/ZK) in combination with irinotecan/5-fluorouracil/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:285, 2003 (abstr 1144)
103. Drevs J, Mross K, Medinger M, et al: Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ ZK22584 (PTK/ZK) in patients with liver metastases. Proc Am Soc Clin Oncol 22:284, 2003 (abstr 1142)
104. George D, Michaelson D, Oh WK, et al: Phase I study of PTK787/ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22:385, 2003 (abstr 1548)
105. Reardon D, Friedman HS, Yung WKA, et al: A phase I trial of PTK787/ZK222584 (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 22:103, 2003 (abstr 412)
106. Roboz GJ, Giles FJ, List AF, et al: Phase I trial PTK787/ZK222584 (PTK/ZK), an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Proc Am Soc Clin Oncol 22:568, 2003 (abstr 2284)
107. Minami H, Ebi H, Tahara M, et al: A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 22:194, 2003 (abstr 778)
108. King J, Zhao J, Clingan P, et al: Randomized double placebo control study of adjuvant treatment with the metalloproteinase inhibitor, marimastat in patients with operable colorectal hepatic metastases: Significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 23:639-645, 2003
109. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167, 2002
110. Anderson I, Supko J, Eder J: Pilot pharmacokinetic study of marimastat (MAR) in combination with carboplatin (C)/Paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small lung cancer (NSCLC). Proc Am Soc Clin Oncol 18:187a, 1999 (abstr 719)
111. Shephard FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical trials group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002
112. Eisenberger M, Sinibaldi V, Laufer M: Phase I/II pharmacokinetic evaluation of marimastat in patients (pts) with advanced prostate cancer (PC): Identification of the biological active dose. Proc Am Soc Clin Oncol 19:336a, 2000 (abstr 1320)
113. Bonomi P: Matrix metalloproteinases and matrix inhibitors in lung cancer. Semin Oncol 29:78-86, 2002
114. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinse inhibitors and cancer trials and tribulations. Science 295:2387-2392, 2002
115. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193, 2001
116. Rosenbaum E, Sinibaldi V, Carducci MA, et al: Evidence of a dose/response relationship with marimastat in patients with biochemically relapsed prostate cancer (pea). Proc Am Soc Clin Oncol 22:436, 2003 (abstr 1762)
117. DeMoraes ED, Fogler WE, Grant D: Recombinant human angiostatin (rhA): A phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 10)
118. Eder JP, Supko JG, Clark JW, et al: Phase I clinical trial of recombinant human Endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20:3772-3784, 2002
119. Herbst RS, Hess KR, Tran HT, et al: Phase I study of recombinant human Endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803, 2002
120. Thomas JP, Arzoomanian RZ, Alberti D, et al: A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223-231, 2003
121. Heymach J, Kulke MH, Fuchs CS, et al: Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin. Proc Am Soc Clin Oncol 22:244, 2003 (abstr 979)
122. Kulke M, Bergsland E, Ryan DP, et al: A phase II, open-label, safety, pharmacokinetic and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol 22:239, 2003 (abstr 958)
123. Eisterer W, Jiang X, Bachelot T, et al: Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther 5:352-359, 2002
124. Gasparini G, Morabito A, Magnani E, et al: Thalidomide: An old sedative-hypnotic with anticancer activity? Current Opin Investig Drugs 2:1302-1308, 2001
125. Neben K, Moehler T, Benner A, et al: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377-3382, 2002
126. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
127. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
128. Cortes J, Kantarjian H, Albitar M, et al: A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97:1234-1241, 2003
129. Eisen T, Boshoff C, Mak I: Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812-817, 2000
130. Motzer RJ, Berg W, Ginsberg M, et al: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302-306, 2002
131. Morabito A, Fanelli M, Carillio G, et al: Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep 11:93-95, 2004
132. Drake MJ, Robson W, Mehta P, et al: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88:822-827, 2003
133. Tseng JE, Glisson BS, Khuri FR, et al: Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92:2364-2373, 2001
134. Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the angiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715, 2000
135. Fine HA, Wen PY, Maher EA, et al: Phase Il trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21:2299-2304, 2003
136. Hwu WJ, Krown SE, Panageas KS, et al: Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial. J Clin Oncol 20:2610-2615, 2002
137. Altorki NK, Keresztes RS, Port JL, et al: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21:2645-2650, 2003
138. Morabito A, Gattuso D, Sarmiento R, et al: Rofecoxib associated with an antiangiogenic schedule of weekly irinotecan and infusional 5-fluorouracil as second line treatment of patients with metastatic colorectal cancer: Results of a dose-finding study. Proc Am Soc Clin Oncol 22:326, 2003 (abstr 1311)
139. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest, 105:1045-1047, 2000
140. Gately S, Kerbel RS: Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7:427-436, 2001
141. Khan J, Wei JS, Ringner M, et al: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural network. Nat Med 7:673-679, 2001
142. Miklos GLG, Maleszka R: Integrating molecular medicine with functional proteomics: Realities and expectations. Proteomics 1:30-41, 2001
143. Weissleder R: Scaling down imaging: Molecular mapping of cancer in mice. Nat Rev Cancer 2:11-18, 2002
144. Pearlman JD, Laham RJ, Post M, et al: Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr Pharm Des 8:1467-1496, 2002
145. Costouros NG, Diehn FE, Libutti SK: Molecular imaging of tumor angiogenesis. J Cell Biochem 39:72-78, 2002 (suppl)
146. Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nat Med 9:123-128, 2003
147. Degani N, Gusis v, Weinstein D, et al: Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 3:780-782, 1997
148. Bacharac SL, Sundaram SK: 18F-FDG in cardiology and oncology: The bitter with the sweet. J Nucl Med 43:1542-1544, 2002
149. Sipkins DA, Cheresm DA, Kazemi MR, et al: Detection of tumor angiogenesis in vivo by alpha v beta-3 target magnetic resonance imaging. Nat Med 4:623-626, 1998
150. 18F- labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785, 2001
151. Herbst RS, Mullani NA, Davis DW, et al: Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814, 2002
152. Morgan B, Thomas AL, Drevs j, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
153. Anderson LH, Yap JT, Miller MP, et al: Assessment of pharmacodynamic vascular response in a phase I trial of Combretastatin A4 phosphate. J Clin Oncol 21:2823-2830, 2003
154. Galbraith SM, Maxwell RJ, Lodge MA, et al: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831-2842, 2003
155. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499, 2002
156. Fox E, Curt GA, Balis FM: Clinical trial design for target-based therapy. Oncologist 7:401-409, 2002
157. Deplanque G, Harris AL: Anti-angiogenic agents: Clinical trial design and therapies in development. Eur J Cancer 36:1713-1724, 2000
158. Collins JM: Functional imaging in phase I studies: Decorations or decision making? J Clin Oncol 21:2807-2809, 2003
159. Gasparini G, Gion M: Molecular-targeted anticancer therapy: Challenges related to study-design and choice of proper end-points. Cancer J 6:117-131, 2000
160. Ruoslathi E: Antiangiogenics meet nanotechnology. Cancer Cell 2:97-98, 2002
161. Isner JM, Asahara T: Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 103:1231-1236, 1999
162. Pennacchietti S, Michieli P, Galluzzo M, et al: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361, 2003
163. Bertolini F, Paul S, Mancuso P, et al: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346, 2003
164. Mullani N, Herbst R, Abbruzzese J, et al: First pass FDG measured blood flow in tumors: A comparative with O-15 labeled water measured blood flow. Clin Positron Imaging 3:153, 2000
165. Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
166. Brown JM: The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F Cain Memorial Award lecture. Cancer Res 59:5863-5870, 1999